Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, United States.
Division of Nephrology and Selzman Institute for Kidney Health, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States.
Am J Physiol Renal Physiol. 2024 Jul 1;327(1):F137-F145. doi: 10.1152/ajprenal.00029.2024. Epub 2024 May 23.
Polymyxins are a last-resort treatment option for multidrug-resistant gram-negative bacterial infections, but they are associated with nephrotoxicity. Gelofusine was previously shown to reduce polymyxin-associated kidney injury in an animal model. However, the mechanism(s) of renal protection has not been fully elucidated. Here, we report the use of a cell culture model to provide insights into the mechanisms of renal protection. Murine epithelial proximal tubular cells were exposed to polymyxin B. Cell viability, lactate dehydrogenase (LDH) release, polymyxin B uptake, mitochondrial superoxide production, nuclear morphology, and apoptosis activation were evaluated with or without concomitant gelofusine. A megalin knockout cell line was used as an uptake inhibition control. Methionine was included in selected experiments as an antioxidant control. A polymyxin B concentration-dependent reduction in cell viability was observed. Increased viability was observed in megalin knockout cells following comparable polymyxin B exposures. Compared with polymyxin B exposure alone, concomitant gelofusine significantly increased cell viability as well as reduced LDH release, polymyxin B uptake, mitochondrial superoxide, and apoptosis. Gelofusine and methionine were more effective at reducing renal cell injury in combination than either agent alone. In conclusion, the mechanisms of renal protection by gelofusine involve decreasing cellular drug uptake, reducing subsequent oxidative stress and apoptosis activation. These findings would be valuable for translational research into clinical strategies to attenuate drug-associated acute kidney injury. Gelofusine is a gelatinous saline solution with the potential to attenuate polymyxin-associated nephrotoxicity. We demonstrated that the mechanisms of gelofusine renal protection involve reducing polymyxin B uptake by proximal tubule cells, limiting subsequent oxidative stress and apoptosis activation. In addition, gelofusine was more effective at reducing cellular injury than a known antioxidant control, methionine, and a megalin knockout cell line, indicating that gelofusine likely has additional pharmacological properties besides only megalin inhibition.
多黏菌素是治疗多重耐药革兰氏阴性菌感染的最后手段,但它们与肾毒性有关。凝胶弗素以前在动物模型中显示可减少多黏菌素相关的肾损伤。然而,其肾保护机制尚未完全阐明。在这里,我们报告使用细胞培养模型提供有关肾保护机制的见解。将鼠上皮近端肾小管细胞暴露于多黏菌素 B。用或不用同时的凝胶弗素评估细胞活力、乳酸脱氢酶 (LDH) 释放、多黏菌素 B 摄取、线粒体超氧化物产生、核形态和细胞凋亡激活。使用巨球蛋白敲除细胞系作为摄取抑制对照。在选定的实验中包括蛋氨酸作为抗氧化剂对照。观察到多黏菌素 B 浓度依赖性降低细胞活力。在类似的多黏菌素 B 暴露后,巨球蛋白敲除细胞中的活力增加。与单独暴露于多黏菌素 B 相比,同时使用凝胶弗素可显著增加细胞活力,减少 LDH 释放、多黏菌素 B 摄取、线粒体超氧化物和细胞凋亡。凝胶弗素和蛋氨酸联合使用比单独使用任何一种药物更能有效减轻肾细胞损伤。总之,凝胶弗素的肾保护机制包括减少细胞内药物摄取,减少随后的氧化应激和细胞凋亡激活。这些发现对于将研究转化为减轻药物相关急性肾损伤的临床策略将是有价值的。凝胶弗素是一种胶状生理盐水溶液,具有减轻多黏菌素相关性肾毒性的潜力。我们证明了凝胶弗素肾保护的机制包括减少近端肾小管细胞摄取多黏菌素 B,限制随后的氧化应激和细胞凋亡激活。此外,凝胶弗素在减轻细胞损伤方面比已知的抗氧化剂对照蛋氨酸和巨球蛋白敲除细胞系更有效,表明凝胶弗素除了巨球蛋白抑制外可能还有其他药理特性。